You are here

  • Home
  • Archive
  • Volume 68, Issue 8
  • Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor α antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor α antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study

Authors

  1. A E Heald, Targeted Genetics Corporation, 1100 Olive Way, Suite 100, Seattle, Washington 98101, USA; alison.heald{at}targen.com
View Full Text

Citation

Mease PJ, Hobbs K, Chalmers A, et al
Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor α antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study
Annals of the Rheumatic Diseases 2009;68:1247-1254.

Publication history

  • Accepted July 26, 2008
  • First published August 4, 2008.
Online issue publication 
March 09, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

2009 BMJ Publishing Group and European League Against Rheumatism